Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

SAN DIEGO and FOSTER CITY, Calif. , Sept. 05, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the completion of the previously announced sale of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).

View Full Press Release